ForteBio, Inc. Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies
Published: Jun 08, 2011
MENLO PARK, Calif., June 8, 2011 /PRNewswire/ -- ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read Anti-Mouse IgG Fc Capture (AMC) biosensor for use on the company's Octet® instrumentation platform. The new biosensor enables high-throughput rapid kinetic characterization and screening of mouse antibodies and other Fc-containing proteins with unprecedented ease of use and cost efficiency.
"With the introduction of our new AMC biosensor, researchers can now benefit from ForteBio's off-the-shelf, label-free biosensors during discovery projects using murine models, as well as when working with human antibodies," said Christopher Silva, ForteBio's vice president of marketing, noting that the company already offers its Anti-Human IgG Fc Capture (AHC) biosensor for analysis of human IgG antibodies. "Our AMC biosensor eliminates the need for inconvenient, labor-intensive steps typically associated with ELISA and SPR methods for screening and kinetic characterization, and thereby facilitates high-throughput research applications such as hybridoma screening and characterization."
The new AMC biosensor enables immobilization of mouse Fc-containing proteins upon the biosensor directly, from a crude or purified matrix, without the need to biotinylate. Additionally, AMC biosensors can be regenerated and reused up to 10 times.
"Our new AMC biosensor can also work fluidly with ForteBio's other research tools for increased speed, ease of use and cost efficiency," said Mr. Silva. "For example, researchers using our Protein G biosensor to titer hybridoma samples can now use our AMC biosensor to perform kinetics and affinity analysis on resulting epitopes of interest all from the same crude sample."
ForteBio's Anti-Human IgG Fc Capture biosensor is ready to use on the company's Octet instruments. ForteBio's Octet platform is based on the company's proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify kinetic characterization and quantitation by eliminating throughput and time-to-result limitations of traditional SPR-based assays and ELISA. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.
ABOUT FORTEBIO, INC.
ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.
SOURCE ForteBio, Inc.